Genmab

News

Denmark's Genmab prepares for $500m US IPO

Antibody-based drugs firm Genmab, noted for developing the blood cancer drug Darzalex with Johnson & Johnson’s Janssen unit, is preparing for a $500 million US IPO.

News

T-cells attacking cancer cell illustration of microscopic photos

‘Trojan horse’ cancer drug shows promise in multiple tumour ...

A new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.

News

J&J rumoured to be sizing up $12bn Genmab acquisition

Speculation mounts that J&J will bid for R&D partner

News

Novartis' Arzerra gains CLL approval

Development partner Genmab says drug approved in relapsed disease.

Denmark's Genmab prepares for $500m US IPO

‘Trojan horse’ cancer drug shows promise in multiple tumour ...

J&J rumoured to be sizing up $12bn Genmab acquisition

Novartis' Arzerra gains CLL approval

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Genmab

Editor's Picks